How a new generation of coronary sinus reducer can significantly expand treatment options for patients with coronary microvascular dysfunction
<p class="moderator speaker-name">Anchorperson: <span classs="personname">Bruce Samuels</span></p><p class="moderator speaker-name">Spokesperson: <span classs="personname">William Wijns</span></p><p class="moderator speaker-name">Discussants: <span classs="personname">Bernard De Bruyne, Francesco Giannini, Alexandra Lansky, Tim Van De Hoef</span></p><p class="moderator speaker-name">Chatmaster: <span classs="personname">Samit Shah</span></p>
Watch this session if you want
<ul> <li>To understand the Reducer therapy mechanism of action for coronary microvascular dysfunction</li> <li>To know the plans of VahatiCor’s for building clinical evidence in coronary microvascular dysfunction</li> <li>To understand AFLUX’s design to simplify the procedure and increase response rate</li> <li>To recognise the importance of diagnosing coronary microvascular dysfunction</li> </ul>
<div class="intervention"><div class="interventionTitle">Welcome and session objectives</div><p class="speaker-intervention-name-img">Bruce Samuels</p></div><div class="intervention"><div class="interventionTitle">Diagnosing a coronary microvascular dysfunction patient</div><p class="speaker-intervention-name-img">Bernard De Bruyne</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Coronary microvascular dysfunction patient case</div><p class="speaker-intervention-name-img">Francesco Giannini</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Coronary sinus reducer and mechanism of action in coronary microvascular dysfunction</div><p class="speaker-intervention-name-img">Tim Van De Hoef</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Clinical path SERRA - Early feasibility study</div><p class="speaker-intervention-name-img">Alexandra Lansky</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Session evaluation and key learnings</div><p class="speaker-intervention-name-img">Bruce Samuels</p></div>